Literature DB >> 8242380

Alterations in the activity of adenylate cyclase and high affinity GTPase in Alzheimer's disease.

B M Ross1, M McLaughlin, M Roberts, G Milligan, J McCulloch, J T Knowler.   

Abstract

The aim of this study was to assess the effect of Alzheimer's disease has on the functional integrity of several signal transduction proteins. The relative levels of the G-protein alpha subunits Gs alpha-L, Gs alpha-S, Gi alpha-2 and G(o) alpha were measured by western blotting and found to be unchanged in membranes prepared from Alzheimer-diseased frontal cortex or hippocampus compared to control brains. However the activity of the G-protein associated enzyme, high affinity GTPase, was found to be reduced in the frontal cortex (reduced by 25%) and by a similar magnitude in the hippocampus (reduced by 27%) of Alzheimer subjects. The same membrane preparations were also assayed for the activity of adenylate cyclase. Basal enzyme activity was not significantly altered in Alzheimer diseased hippocampus, but was markedly reduced (by 45%) in the frontal cortex. The ability of fluoride and aluminium ions to stimulate adenylate cyclase was not significantly changed in either brain region. This suggests that G-proteins, especially Gs, are still able to interact with this enzyme. These results indicate that although the presence of Alzheimer's disease does not significantly alter G-protein levels, changes have taken place in the overall activity of these proteins. However this alteration does not affect their ability to stimulate adenylate cyclase activity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8242380     DOI: 10.1016/0006-8993(93)90798-r

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  5 in total

1.  Amyloid beta-peptide disrupts carbachol-induced muscarinic cholinergic signal transduction in cortical neurons.

Authors:  J F Kelly; K Furukawa; S W Barger; M R Rengen; R J Mark; E M Blanc; G S Roth; M P Mattson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

2.  Complex noradrenergic dysfunction in Alzheimer's disease: Low norepinephrine input is not always to blame.

Authors:  Mary Gannon; Qin Wang
Journal:  Brain Res       Date:  2018-01-04       Impact factor: 3.252

3.  Quantitative proteomic analysis of mitochondria from primary neuron cultures treated with amyloid beta peptide.

Authors:  Mark A Lovell; Shuling Xiong; William R Markesbery; Bert C Lynn
Journal:  Neurochem Res       Date:  2005-01       Impact factor: 3.996

Review 4.  Disturbances in signal transduction mechanisms in Alzheimer's disease.

Authors:  C J Fowler; R F Cowburn; A Garlind; B Winblad; C O'Neill
Journal:  Mol Cell Biochem       Date:  1995 Aug-Sep       Impact factor: 3.396

Review 5.  Understanding PDE4's function in Alzheimer's disease; a target for novel therapeutic approaches.

Authors:  Amy J Tibbo; Gonzalo S Tejeda; George S Baillie
Journal:  Biochem Soc Trans       Date:  2019-10-31       Impact factor: 5.407

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.